Loading…
Reliance Pharma Fund
Disclosed for 84 months, Sep 2012 to Aug 2019. This scheme is no longer reporting.Published as: RELIANCE PHARMA FUND (An Open Ended Equity Scheme Investing In Pharma Sector)
Portfolio value
₹1,794 Cr
up ₹107 Cr vs Oct 2017
Reliance Pharma Fund is an active equity fund in the Sectoral / Thematic category from Nippon India Mutual Fund. In November 2017 it disclosed 19 stocks worth ₹1,794 Cr, up ₹107 Cr from Oct 2017. Its largest positions were Divi's Laboratories Limited (11.6%), Abbott India Limited (9.7%), Cipla Limited (8.7%); the ten largest together made up 81.2% of the portfolio, and Pharmaceuticals & Biotechnology was the biggest sector at 83.1% of its equity. Cash and debt stood at 1.3%. Compared with Oct 2017 the fund entered 2 new stocks and exited 0.
Against 227 other Sectoral / Thematic funds
Concentration
99%
Top-10 weight is higher than 99% of peers
Breadth
4%
Holds more stocks than 4% of peers
Cash
15%
Holds more cash than 15% of peers
Holdings in November 2017
Download CSVEvery line the fund disclosed, with the change against Oct 2017. Click a column to sort; click a company to see every fund that owns it.
| Divi's Laboratories Limited | 11.60% | up 1.14 pts | ₹208 Cr | up ₹31.7 Cr | Added |
| Abbott India Limited | 9.71% | up 1.68 pts | ₹174 Cr | up ₹38.7 Cr | Added |
| Cipla Limited | 8.71% | down 0.41 pts | ₹156 Cr | up ₹2.5 Cr | Added |
| Sun Pharmaceutical Industries Limited | 8.58% | down 0.93 pts | ₹154 Cr | down ₹6.5 Cr | Trimmed |
| Dr. Reddy's Laboratories Limited | 8.54% | down 1.12 pts | ₹153 Cr | down ₹9.7 Cr | Trimmed |
| Biocon Limited | 8.17% | up 3.04 pts | ₹147 Cr | up ₹60.1 Cr | Added |
| Aurobindo Pharma Limited | 7.72% | down 0.39 pts | ₹139 Cr | up ₹1.8 Cr | Added |
| Sanofi India Limited | 7.49% | down 0.06 pts | ₹134 Cr | up ₹7 Cr | Added |
| Thyrocare Technologies Limited | 6.03% | down 0.68 pts | ₹108 Cr | down ₹5.1 Cr | Trimmed |
| Torrent Pharmaceuticals Limited | 4.61% | down 0.23 pts | ₹82.8 Cr | up ₹1 Cr | Added |
| Lupin Limited | 3.87% | down 1.31 pts | ₹69.5 Cr | down ₹17.9 Cr | Trimmed |
| Healthcare Global Enterprises Limited | 2.86% | down 0.48 pts | ₹51.4 Cr | down ₹5.1 Cr | Trimmed |
| Glenmark Pharmaceuticals Limited | 2.20% | down 0.36 pts | ₹39.5 Cr | down ₹3.8 Cr | Trimmed |
| Max India Limited | 2.19% | down 0.10 pts | ₹39.2 Cr | up ₹60 L | Added |
| Narayana Hrudayalaya Limited | 2.14% | down 0.20 pts | ₹38.5 Cr | down ₹1 Cr | Trimmed |
| Apollo Hospitals Enterprise Limited | 1.78% | up 1.78 pts | ₹31.9 Cr | up ₹31.9 Cr | New |
| Cash, TREPS & receivables | 1.27% | down 0.50 pts | ₹22.7 Cr | down ₹7.1 Cr | Trimmed |
| Indoco Remedies Limited | 1.12% | down 0.01 pts | ₹20.1 Cr | up ₹99 L | Added |
| Alkem Laboratories Limited | 0.78% | down <0.01 pts | ₹14 Cr | up ₹80 L | Added |
| Syngene International Limited | 0.62% | up 0.62 pts | ₹11.1 Cr | up ₹11.1 Cr | New |
What changed, Oct 2017 to Nov 2017
New New positions (2)
- Apollo Hospitals Enterprise Limited1.8% · ₹31.9 Cr
- Syngene International Limited0.6% · ₹11.1 Cr
Exited Exited (0)
None.
Added Biggest additions
- Biocon Limitedup ₹60.1 Cr (+3.04% pts)
- Abbott India Limitedup ₹38.7 Cr (+1.68% pts)
- Divi's Laboratories Limitedup ₹31.7 Cr (+1.14% pts)
- Sanofi India Limited
Sectors
Which sectors the fund is moving towards and away from, and where its money sits now. Shares are of the fund’s classified equity holdings, so they add up to 100%.
Where the weight moved
Compared with
Since Oct 2017, the weight rose most in Healthcare Services (+0.6 pts), and fell most in Pharmaceuticals & Biotechnology (−0.6 pts).
- Healthcare Services15.2% → 15.8%+0.6 pts
- Pharmaceuticals & Biotechnology83.7% → 83.1%−0.6 pts
A sector’s weight changes when the fund buys or sells, and also when its shares rise or fall in price, so a change is not by itself a sign of buying or selling.
Main sectors’ weights over time
| Sector | Nov 2014 | Nov 2016 | May 2017 | Aug 2017 | Oct 2017 | Nov 2017 |
|---|---|---|---|---|---|---|
| Pharmaceuticals & Biotechnology | 95.4% | 84.3% | 85.3% | 83.6% | 83.7% | 83.1% |
| Healthcare Services | — | 15.7% | 14.7% | 16.4% | 15.2% | 15.8% |
| Pharmaceuticals | 3.6% | — | — | — | 1.2% | 1.1% |
Allocation in Nov 2017change vs Oct 2017
- Pharmaceuticals & Biotechnology (12)83.1%▼ 0.6 pts
- Healthcare Services (6)15.8%▲ 0.6 pts
- Pharmaceuticals (1)1.1%
Cash and debt
The share of the portfolio not in shares: cash and net receivables, money-market instruments and bonds, as disclosed each month. Cash can dip below zero when payables, often on derivative positions, exceed it. A change here describes what the fund did; it is not a signal.
Cash & debt, Nov 2017
1.3%
▼ 2.0 pts vs Oct 2017
- Cash alone
- 1.3%
- cash and net receivables
- A year earlier
- 0.7%
- Nov 2016 · now ▲ 0.6 pts
- Last 12 months
- 0.4% – 5.8%
- lowest to highest · record 9.6% in Nov 2015
History
Disclosed portfolio value by month, with the stocks the fund entered and exited against its previous disclosure. Every month is a link to that portfolio.